Huawei Visits Hybio Pharmaceutical to Explore New AI Drug Discovery Collaboration
On the afternoon of December 31, 2024, a four-member delegation from Huawei Technologies Co., Ltd. paid a visit to Hybio Pharmaceutical for exchanges and cooperation discussions. The delegation included Li Songmeng, General Manager of Shenzhen Government & Enterprise Pan-Enterprise Systems Department; Dong Wei, Director of Shenzhen Government & Enterprise Intelligent Manufacturing Development Department; Wang Xiang, Director of Shenzhen Cloud-Native Biomedical Solutions; and Dai Yunlong, Shenzhen Government & Enterprise Biomedical Industry Representative. Hybio Pharmaceutical's senior management, including Zeng Shaogui, Chairman and President; Yu Pinxiang, Director and Executive President; Xu Liyong, Independent Director; Tang Yangming, Director and Vice President; and Yang Di, Director and Vice President, extended a warm reception to the visiting Huawei delegation.
During their visit to Hybio Pharmaceutical's product exhibition hall and R&D center, the Huawei delegation gained a deep understanding of Hybio Pharmaceutical's strategic vision, development history, product pipeline, and R&D technologies. They highly praised Hybio Pharmaceutical's 26 years of accumulated experience in Peptide Drug manufacturing and R&D technology.
In the subsequent meeting, both parties had an in-depth discussion on the application of Huawei Cloud's Pangu drug molecule model in areas such as drug design and development, peptide platform construction, and digital transformation to enhance corporate efficiency. They also discussed the application prospects of artificial intelligence in the global pharmaceutical industry. Huawei's AI applications were seen as a key technology to accelerate the company's global expansion.
General Manager Li Songmeng emphasized that Huawei Cloud's healthcare solutions, built on a robust cloud computing architecture and cutting-edge AI algorithms, have developed the Pangu drug molecule large model, aiming to accelerate the high-quality development of the healthcare industry. Huawei Cloud is also continuously advancing the application of the Pangu large model in scenarios such as target discovery, drug design, and clinical research, and looks forward to exploring cooperation opportunities with Hybio Pharmaceutical in the field of peptide drugs and sharing cooperation achievements.
Chairman Zeng Shaogui elaborated on the company's core technological advantages and practical experience in the drug development-to-application process. He stated that Hybio Pharmaceutical has always adhered to R&D and production quality-driven approaches, continuously explored the integrated development of cutting-edge technologies and the pharmaceutical industry, and actively sought high-quality partners for complementary advantages. He believes that Huawei Cloud's Pangu medical large model can realize numerous core application scenarios in AI Drug Discovery, accelerate the drug R&D process, and improve enterprise operational efficiency. Chairman Zeng Shaogui expressed hope that through this exchange, both parties can spark new ideas, identify multi-faceted cooperation opportunities in the future, and jointly promote the high-quality development of the pharmaceutical industry.
Globally, artificial intelligence is emerging as a key driver in the pharmaceutical industry. The application of AI technologies not only accelerates the new drug R&D process and reduces costs, but also enhances the precision and safety of pharmaceuticals. Through technologies such as big data analytics, machine learning, and deep learning, AI can predict the activity of drug molecules, optimize drug design, and even provide personalized treatment plans during the clinical trial phase. With the continuous advancement of AI technologies, their application prospects in the global pharmaceutical industry are broad, holding the promise of bringing more innovative drugs and treatment options to patients.
Looking ahead, Hybio Pharmaceutical will continue to adhere to its development strategy of "Talent, Generic-Innovation, and Internationalization," maintain unimpeded communication channels with Huawei, jointly explore strategic cooperation directions, inject new impetus into enterprise development, and collectively promote innovation and progress in the pharmaceutical industry.
About Hybio Pharmaceutical:
Hybio Pharmaceutical is a high-tech enterprise specializing in the research and development as well as manufacturing of peptide drugs, with 26 years of technical accumulation and industry experience. The company is committed to driving the development of the pharmaceutical industry through innovative technologies and providing high-quality treatment solutions for patients worldwide.
About Huawei Technologies Co., Ltd.:
Huawei Technologies Co., Ltd. is a world-leading provider of information and communication technology (ICT) solutions, dedicated to building a fully connected world. Huawei Cloud Services helps various industries achieve digital transformation by offering powerful cloud computing and artificial intelligence technologies.